Intimation Under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 - Commencement of Commercial Production of Phase II of Greenfield Facility at Tarapur.

September 24, 2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th Floor, Plot No.C/1, G Block, Dalal Street, Fort, Bandra Kurla Complex, Bandra East, Mumbai 400 001. Mumbai 400 051. Scrip Code: 524774 Symbol: NGLFINE Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Commencement of Commercial Production of Phase II of Greenfield Facility at Tarapur. Dear Sir/Madam, Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and in continuation of the Company’s earlier disclosures dated March 25, 2025 and August 7, 2025 regarding the Greenfield expansion facility at Tarapur, we wish to inform you that Phase II of the Greenfield facility has commenced commercial production with effect from September 24, 2026. The Company had earlier intimated that Phase I of the Greenfield facility commenced commercial production with effect from March 11, 2025. The facility has been developed and operationalised in phases with the objective of augmenting the Company’s manufacturing infrastructure and enabling it to meet the requirements of its diverse product portfolio. With the commencement of commercial production of Phase II, the Greenfield facility at Tarapur has been fully commissioned and operationalised. The Company manufactures a wide variety of active pharmaceutical ingredients, each having different manufacturing processes, batch sizes, cycle times, yields, equipment requirements and production characteristics. Accordingly, the aggregate installed capacity cannot be meaningfully expressed as a single uniform quantity, such as tonnes per annum, since the actual production capacity varies depending on the product mix and the type of API manufactured. The capacity addition is therefore intended to be utilised flexibly across the Company’s diverse API product portfolio, based on product requirements, manufacturing schedules and available plant and equipment resources. The total investment made towards the Greenfield expansion facility up to September 24, 2026 is approx. ₹222crore. The project has been financed through [internal accruals / borrowings / a combination of internal accruals and borrowings]. The relevant details are set out below: Particulars Details Nature of event Commencement of commercial production of Phase II of the Greenfield facility. Location Tarapur, Maharashtra. Date of commencement of September 24, 2026 commercial production Existing capacity Not stated as a single aggregate quantity, as capacity varies with product mix and API manufactured. Capacity addition Flexible manufacturing capacity for a diverse range of APIs; a single uniform capacity figure is not commercially representative. Total capacity after expansion To be determined with reference to the product mix and API manufactured. Investment made ₹222 crore Mode of financing Term Loan from Banks ₹84 crore. Internal Accruals ₹138 crore. Rationale To augment manufacturing infrastructure and provide flexible capacity for the Company’s diverse API product portfolio. The Company will continue to disclose quantitative production or capacity information wherever such information is relevant and meaningfully determinable for a particular API, product category or product mix. This intimation shall also be available on the Company’s website at www.nglfinechem.com. You are requested to take the above information on record. Thanking you, Yours faithfully, For NGL Fine-Chem Limited Shivam Gharat Company Secretary and Compliance Officer M. No.: A56704